Core Viewpoint - Company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance international strategy and attract talent [3][8] Financial Performance - In 2024, the company achieved a net profit of 1.412 billion yuan, a year-on-year increase of 213.1%, marking the highest level since its listing [1][8] - The company's revenue for 2024 was 3.639 billion yuan, up 59.2% year-on-year, with overseas revenue contributing 2.577 billion yuan, accounting for 70.8% of total revenue [1][10] - The gross profit margin for overseas sales was 62.82%, an increase of 0.77 percentage points year-on-year [1][10] Shareholder Returns - The company has announced a share repurchase plan of 200 million to 400 million yuan, which will bring total cash dividends and share repurchases to 3.349 billion yuan since its listing [2][7] - The company has consistently implemented dividends over the past six years, totaling approximately 2.14 billion yuan [4][5] R&D and Innovation - Approximately 75% of the company's employees are engaged in research and development, with R&D expenses in 2024 amounting to 763 million yuan, representing 20.98% of total revenue [8][10] - The company holds 187 authorized invention patents and has maintained a high R&D expense ratio exceeding 15% for three consecutive years [10] Market Position and Growth - The company is a leading player in the memory interface chip market, benefiting from the growing demand for DDR5 memory interface chips and high-performance computing chips driven by the AI industry [9][10] - As of April 22, 2025, the company expects to deliver interconnect chips with a total order value exceeding 1.29 billion yuan [9]

郭晨凯 制图 ◎记者 柴刘斌 2025年行至年中，上市公司二季度的经营发展概况也逐渐明朗。近日，不少上市公司在业绩说明会、机 构调研中主动透露主营业务发展的新动向，积极传递产业升级的新信号。有的公司"报喜"项目建设新进 展，有的公司晒出新技术与新订单，还有的公司积极探寻并购重组新方向。 从半导体到机器人，从新能源到新材料，来自新兴产业、未来产业的上市公司用客观的数据、饱满的订 单、充沛的产能、国际化的视野，诉说着经营图景里的"稳"与"进"，战略布局中的"守"与"变"。 多维度传递二季度经营暖意 5月以来，机构投资者扎堆涌进上市公司打探订单规模、产能利用率、重大项目进展等经营新动向。上 海证券报记者发现，高景气赛道延续强劲增长动能，周期行业在供需调整中寻找平衡，制造业企业则专 注产能效率提升与市场需求升级。 受益于AI产业发展，芯片公司以订单增长量折射出产业高景气度。 "截至4月22日，预计在2025年第二季度交付的互连类芯片在手订单金额合计已超过人民币12.9亿元。同 时，公司仍在陆续收到客户的新订单。"澜起科技表示，展望2025年全年，预计DDR5内存接口芯片需 求及渗透率较2024年大幅提升，高性能运力芯 ...

申请入围"中国IC独角兽" 半导体高质量发展创新成果征集 问题4:公司将全互连芯片作为未来五至十年的战略重心,这个领域的发展潜力如何?公司有哪些优势能够 支撑在全互连芯片的不断延展? 答复:互连芯片主要用于提升系统运力,从当前智算系统的发展趋势来看,更高带宽和更低延迟的互连芯片 是提升系统整体效率的刚需。同时,由于智算系统的复杂架构,系统需要多种功能的互连芯片协同工作,比 如芯片间的互连、服务器机箱之间互连、服务器集群间互连以及数据中心间的互连等。因此,互连芯片 正逐渐成长为一个有巨大潜力的蓝海市场。澜起科技在互连芯片领域深耕20余年,拥有深厚的技术积 累。同时,公司深度参与相关国际标准组织与产业联盟的标准制定工作,并基于这些新标准持续研发高性 问题1:公司互连类芯片一季度实现大幅增长,请问二季度是否能延续这一趋势?如何看待2025年全年运力 芯片的需求情况? 答复:2025年第一季度,公司互连类芯片产品线销售收入为11.39亿元,同比增长63.92%,环比增长17.19%,已 实现连续八个季度环比增长。根据公司披露的《2025年第一季度报告》,受益于AI产业趋势对DDR5内存 接口芯片及高性能运力芯片需求的 ...

（原标题：基本面与技术面齐飞！这些股成机构心头肉） A股公司2025年一季度报告正处于密集披露阶段。 目前，上市公司定期报告仅提供同比数据。然而，在评估上市公司发展趋势和判断拐点时，季度环比数据具有更高的敏感性和及时性，相比之 下，其价值更为突出。因此，若同时综合考虑同比和环比数据，将更有助于全面、准确地评估上市公司的经营状况。 27股净利润环比同比三连增 据证券时报·数据宝统计，截至4月26日，在已披露2025年一季报的A股公司中，剔除北交所个股和今年一季度仍处于亏损状态的个股后，2024年三 季度至2025年一季度，单季度净利润环比同比均保持增长的个股有27只。 从行业分布来看，27股分布于18个申万二级行业，其中半导体行业个股相对较多。 东莞证券指出，从自主可控角度，近期贸易摩擦加剧有望加快半导体设备与材料、高端算力芯片、射频模组等产品的国产替代进程，建议结合 2024年和今年一季度业绩情况，从AI驱动和国产替代角度把握相关细分领域投资机会。 从半导体行业个股来看，澜起科技、芯朋微、寒武纪-U、恒玄科技4股业绩环比同比三连增，其中澜起科技获22家机构评级，机构关注度最高。 澜起科技今年一季度实现营收12 ...

Group 1: Key Insights on Electronic Industry - The report highlights that 澜起科技 has achieved continuous quarter-on-quarter growth in revenue and net profit for eight consecutive quarters, driven by the demand for interconnected chips [4][6] - For Q1 2025, the company reported a revenue of 1.22 billion yuan, representing a year-on-year increase of 65.78% and a quarter-on-quarter increase of 14.43%, with a net profit of 525 million yuan, up 135.14% year-on-year [4][5] - The demand for DDR5 memory interface chips and high-performance interconnect chips is expected to continue growing, with significant orders in hand exceeding 1.29 billion yuan as of April 22, 2025 [6] Group 2: Key Insights on Petrochemical Industry - 恒力石化 reported a total revenue of 236.40 billion yuan for 2024, a year-on-year increase of 0.65%, with a net profit of 7.04 billion yuan, up 2.01% [8][9] - In Q1 2025, the company achieved a revenue of 57.05 billion yuan, a decrease of 2.34% year-on-year, and a net profit of 2.05 billion yuan, down 4.13% [8][9] - The company has seen a significant increase in new materials sales, with production of high-performance resins and new materials reaching 1.60 million tons per year, contributing to the overall growth [10][11] Group 3: Key Insights on Pharmaceutical Industry - 华东医药 reported a total revenue of 41.91 billion yuan for 2024, reflecting a year-on-year growth of 3.16%, with a net profit of 3.51 billion yuan, up 23.72% [14][15] - The company’s industrial business has become a core growth driver, with the pharmaceutical industrial segment achieving a revenue of 13.81 billion yuan, a year-on-year increase of 13.05% [15][16] - R&D investment in the pharmaceutical sector reached 2.68 billion yuan in 2024, marking a 16.77% increase, with a focus on endocrine, autoimmune, and oncology fields [16]